Analysis of High-Yield Stock Investment Opportunities
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 28 2026
0mins
Should l Buy PFE?
Source: Fool
- Pfizer's Outlook: Pfizer boasts a forward dividend yield of 6.4%, and despite facing poor financial results and increased competition, its robust portfolio of medicines and the launch of new products are expected to support dividend sustainability, particularly with significant sales growth from the 2023-approved Abrysvo vaccine and Elrexfio cancer drug.
- Medical Properties Trust's Challenges: Medical Properties Trust (MPT) has faced tenant defaults and bankruptcies over the past few years; however, the company has successfully diversified by cutting dividends and selling assets, thereby reducing reliance on any single tenant and enhancing long-term stability.
- Dividend Safety Analysis: Despite an uncertain economic outlook, MPT's forward dividend yield stands at 7%, and medical-focused REITs are considered relatively safe; MPT's management has expressed confidence in the recovery of its business and announced a dividend increase last year, demonstrating a commitment to shareholder returns.
- Long-Term Investment Appeal: Although MPT's stock has significantly declined over the past three years, it remains well-positioned for strong performance as its business stabilizes, making it an attractive high-yield stock choice for income-seeking investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 25.330
Low
24.00
Averages
28.56
High
35.00
Current: 25.330
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Astellas Unveils New Oncology Data at ASCO Meeting
- Oncology Commitment: Astellas will present new data from its oncology portfolio at the 2026 ASCO Annual Meeting, reinforcing its long-term commitment to improving outcomes for cancer patients, which is expected to enhance its market position in cancer treatment.
- Bladder Cancer Research Progress: In bladder cancer, Astellas will showcase 3.5-year follow-up data from the EV-302 study evaluating the efficacy of enfortumab vedotin combined with pembrolizumab, providing crucial insights into treatment durability that may influence future clinical management decisions.
- Prostate Cancer Clinical Analysis: For prostate cancer, Astellas will share analyses from established clinical programs like EMBARK and ARCHES, offering further insights into treatment outcomes for patients with varying clinical characteristics, thereby supporting clinical decision-making and optimizing treatment strategies.
- Women's Health New Trial: Astellas will introduce the progress of the HIGHLIGHT 1 trial at ASCO, investigating the safety and efficacy of fezolinetant in women with hormone receptor-positive breast cancer receiving endocrine therapy, potentially providing new treatment options in women's health.
See More
Anti-Vaccine Bills Fail Amid Public Health Advocacy
- Anti-Vaccine Bill Failures: Dozens of anti-vaccine bills backed by the 'Make America Healthy Again' coalition have failed, indicating limited political power among supporters and showcasing the effectiveness of public health advocacy.
- Public Support for Vaccination: A February poll revealed that a bipartisan majority of Americans favor school vaccination mandates and view vaccines as safe for children, which has hindered the progress of anti-vaccine legislation in several states.
- Legislative Dynamics Shift: Despite a surge in anti-vaccine bills, particularly in states like Idaho and West Virginia, none have passed, underscoring the prioritization of public health policies over anti-vaccine initiatives.
- Future Legislative Expectations: Both public health advocates and anti-vaccine proponents anticipate ongoing debates over vaccine policies in state legislatures, suggesting that the influence of the anti-vaccine movement is rising and may lead to more proposed legislation.
See More
Honeywell's Underperformance Affects Dow Jones Index
- Dow Component Changes: Honeywell replaced Raytheon Technologies in the Dow on August 31, 2020, but has only delivered a 56.2% total return since then, significantly lagging behind RTX's 231.1%, indicating its failure to meet market expectations.
- Unfulfilled Innovation Potential: Although Honeywell was viewed as a diversified and innovative industrial giant in 2020, its persistent underperformance in earnings and free cash flow growth, partly due to supply chain and inflationary pressures, has hindered its ability to capitalize on its strengths.
- Spinoff Plans Generate Interest: In November 2024, activist investor Elliott Investment Management amassed a position exceeding $5 billion, prompting Honeywell to consider a breakup; the successful spinoff of Solstice Advanced Materials in October 2025, which saw a 79.4% gain, highlights the potential for growth through such restructuring.
- Future Outlook and Market Reaction: Honeywell plans to spin off its aerospace division on June 29, 2024, with the remaining business focusing on industrial and building automation, and the market anticipates that this structural adjustment could enhance its standing in the Dow, reflecting a broader preference for focused companies.
See More
Acting FDA CDER Leader Expected to Step Down
- Leadership Change: Following Marty Makary's resignation as FDA Commissioner on May 12, acting CDER Director Tracey Beth Hoeg is also expected to step down, indicating instability at the FDA that could impact drug approval processes.
- Tenure Background: Hoeg has served as acting director since December 2025 and joined the FDA in March 2025 as a special assistant and senior advisor to Makary, highlighting her rapid ascent and influence within the agency.
- Professional Background: Trained as a sports medicine physician and epidemiologist, Hoeg criticized school closures during the COVID-19 pandemic, suggesting her public health policy stance may influence FDA decision-making.
- Market Reaction: The leadership changes at the FDA could create uncertainty in the biopharmaceutical sector, particularly regarding partnerships and R&D with countries like China, potentially affecting future deal-making and investment strategies.
See More
Bristol Myers Squibb Partners with Hengrui Pharma for Drug Development
- Significant Partnership: Bristol Myers Squibb has announced a potential multi-billion dollar partnership with Hengrui Pharma, aiming to co-develop around a dozen drugs, including four that Bristol will send to China for early-stage clinical trials, marking a new phase of international collaboration in drug development.
- Shift in R&D Model: This collaboration represents a departure from traditional licensing agreements, as both companies will contribute resources to drug development, positioning China as a vital part of the global pharmaceutical R&D ecosystem and highlighting U.S. drugmakers' increasing focus on the Chinese market.
- Market Trend Shift: According to DealForma, over half of large pharmaceutical licensing deals this year have originated from China, up from 39% last year, indicating a growing trend among U.S. and European biopharmaceutical companies to shift early drug development to China to expedite market entry.
- Future Industry Outlook: Experts predict that early-stage drug discovery will increasingly move to China due to its ability to conduct studies at lower costs and faster timelines, potentially reshaping the U.S. pharmaceutical landscape and encouraging more companies to initiate early clinical trials in China.
See More
Bristol Myers Squibb Partners with Hengrui Pharma for Drug Development
- New Drug Collaboration: Bristol Myers Squibb has announced a potential multi-billion dollar partnership with China's Hengrui Pharma to jointly develop about a dozen drugs, including four experimental drugs that will be sent to China for early clinical trials, marking a new phase in cross-continental drug development.
- Significance of the Chinese Market: According to DealForma, over half of large pharmaceutical companies' licensing deals have originated from China this year, a significant increase from 39% last year, indicating a growing focus of American and European biopharmaceutical companies on the Chinese market, which could accelerate the introduction of new drugs.
- Shift in R&D Model: This partnership not only involves sending experimental drugs to China for development but also positions China as a crucial part of the global R&D ecosystem, reflecting the pharmaceutical industry's recognition of China's innovative capabilities and potentially altering the future landscape of drug development.
- Signal of Industry Transformation: As more companies conduct early drug development in China, industry experts believe this will enhance drug development efficiency and reduce costs, potentially challenging the traditional U.S. early drug discovery model and prompting global pharmaceutical companies to reassess their R&D strategies.
See More
Astellas Unveils New Oncology Data at ASCO Meeting
- Oncology Commitment: Astellas will present new data from its oncology portfolio at the 2026 ASCO Annual Meeting, reinforcing its long-term commitment to improving outcomes for cancer patients, which is expected to enhance its market position in cancer treatment.
- Bladder Cancer Research Progress: In bladder cancer, Astellas will showcase 3.5-year follow-up data from the EV-302 study evaluating the efficacy of enfortumab vedotin combined with pembrolizumab, providing crucial insights into treatment durability that may influence future clinical management decisions.
- Prostate Cancer Clinical Analysis: For prostate cancer, Astellas will share analyses from established clinical programs like EMBARK and ARCHES, offering further insights into treatment outcomes for patients with varying clinical characteristics, thereby supporting clinical decision-making and optimizing treatment strategies.
- Women's Health New Trial: Astellas will introduce the progress of the HIGHLIGHT 1 trial at ASCO, investigating the safety and efficacy of fezolinetant in women with hormone receptor-positive breast cancer receiving endocrine therapy, potentially providing new treatment options in women's health.
See More
Anti-Vaccine Bills Fail Amid Public Health Advocacy
- Anti-Vaccine Bill Failures: Dozens of anti-vaccine bills backed by the 'Make America Healthy Again' coalition have failed, indicating limited political power among supporters and showcasing the effectiveness of public health advocacy.
- Public Support for Vaccination: A February poll revealed that a bipartisan majority of Americans favor school vaccination mandates and view vaccines as safe for children, which has hindered the progress of anti-vaccine legislation in several states.
- Legislative Dynamics Shift: Despite a surge in anti-vaccine bills, particularly in states like Idaho and West Virginia, none have passed, underscoring the prioritization of public health policies over anti-vaccine initiatives.
- Future Legislative Expectations: Both public health advocates and anti-vaccine proponents anticipate ongoing debates over vaccine policies in state legislatures, suggesting that the influence of the anti-vaccine movement is rising and may lead to more proposed legislation.
See More
Honeywell's Underperformance Affects Dow Jones Index
- Dow Component Changes: Honeywell replaced Raytheon Technologies in the Dow on August 31, 2020, but has only delivered a 56.2% total return since then, significantly lagging behind RTX's 231.1%, indicating its failure to meet market expectations.
- Unfulfilled Innovation Potential: Although Honeywell was viewed as a diversified and innovative industrial giant in 2020, its persistent underperformance in earnings and free cash flow growth, partly due to supply chain and inflationary pressures, has hindered its ability to capitalize on its strengths.
- Spinoff Plans Generate Interest: In November 2024, activist investor Elliott Investment Management amassed a position exceeding $5 billion, prompting Honeywell to consider a breakup; the successful spinoff of Solstice Advanced Materials in October 2025, which saw a 79.4% gain, highlights the potential for growth through such restructuring.
- Future Outlook and Market Reaction: Honeywell plans to spin off its aerospace division on June 29, 2024, with the remaining business focusing on industrial and building automation, and the market anticipates that this structural adjustment could enhance its standing in the Dow, reflecting a broader preference for focused companies.
See More
Acting FDA CDER Leader Expected to Step Down
- Leadership Change: Following Marty Makary's resignation as FDA Commissioner on May 12, acting CDER Director Tracey Beth Hoeg is also expected to step down, indicating instability at the FDA that could impact drug approval processes.
- Tenure Background: Hoeg has served as acting director since December 2025 and joined the FDA in March 2025 as a special assistant and senior advisor to Makary, highlighting her rapid ascent and influence within the agency.
- Professional Background: Trained as a sports medicine physician and epidemiologist, Hoeg criticized school closures during the COVID-19 pandemic, suggesting her public health policy stance may influence FDA decision-making.
- Market Reaction: The leadership changes at the FDA could create uncertainty in the biopharmaceutical sector, particularly regarding partnerships and R&D with countries like China, potentially affecting future deal-making and investment strategies.
See More
Bristol Myers Squibb Partners with Hengrui Pharma for Drug Development
- Significant Partnership: Bristol Myers Squibb has announced a potential multi-billion dollar partnership with Hengrui Pharma, aiming to co-develop around a dozen drugs, including four that Bristol will send to China for early-stage clinical trials, marking a new phase of international collaboration in drug development.
- Shift in R&D Model: This collaboration represents a departure from traditional licensing agreements, as both companies will contribute resources to drug development, positioning China as a vital part of the global pharmaceutical R&D ecosystem and highlighting U.S. drugmakers' increasing focus on the Chinese market.
- Market Trend Shift: According to DealForma, over half of large pharmaceutical licensing deals this year have originated from China, up from 39% last year, indicating a growing trend among U.S. and European biopharmaceutical companies to shift early drug development to China to expedite market entry.
- Future Industry Outlook: Experts predict that early-stage drug discovery will increasingly move to China due to its ability to conduct studies at lower costs and faster timelines, potentially reshaping the U.S. pharmaceutical landscape and encouraging more companies to initiate early clinical trials in China.
See More
Bristol Myers Squibb Partners with Hengrui Pharma for Drug Development
- New Drug Collaboration: Bristol Myers Squibb has announced a potential multi-billion dollar partnership with China's Hengrui Pharma to jointly develop about a dozen drugs, including four experimental drugs that will be sent to China for early clinical trials, marking a new phase in cross-continental drug development.
- Significance of the Chinese Market: According to DealForma, over half of large pharmaceutical companies' licensing deals have originated from China this year, a significant increase from 39% last year, indicating a growing focus of American and European biopharmaceutical companies on the Chinese market, which could accelerate the introduction of new drugs.
- Shift in R&D Model: This partnership not only involves sending experimental drugs to China for development but also positions China as a crucial part of the global R&D ecosystem, reflecting the pharmaceutical industry's recognition of China's innovative capabilities and potentially altering the future landscape of drug development.
- Signal of Industry Transformation: As more companies conduct early drug development in China, industry experts believe this will enhance drug development efficiency and reduce costs, potentially challenging the traditional U.S. early drug discovery model and prompting global pharmaceutical companies to reassess their R&D strategies.
See More
